16 companies decline by double-digit… Youngil Pharm falls in half
The joy and sorrow of medium and large companies coexist in the pharmaceutical market.
According to IQVIA, 116 pharmaceutical companies made more than KRW 10 billion in sales in the first quarter of last year or this first quarter, of which 21 recorded double-digit growth and 16 companies saw negative double-digit growth.
Eden Pharma’s growth was the most outstanding. Eden Pharma, which recorded KRW 5.6 billion in sales in 1Q of last year, grew 86.4% to KRW 10.5 billion in 1Q of this year.
Ibsen rose 45% from KRW 7.8 billion to KRW 11.3 billion, and Amgen grew 41.7% from KRW 26.7 billion to KRW 37.9 billion, recording the highest growth among existing KRW 10 billion mark companies.
Followed by the top three companies, Celgene grew 33.7% from KRW 15.1 billion to KRW 20 billion mark, YooYoung Pharmaceutical 26.8% from KRW 14.2 billion to KRW 18.1 billion, Boryung Biopharma 20.27% from KRW 11.7 billion to KRW 14.1 billion, and Myungmoon Pharmaceutical 20.18% from KRW 18.8 billion to KRW 22.6 billion.
Moreover, Medica Korea, Hwanin Pharmaceutical, Celltrion Pharm, Ono Pharmaceutical, Taejoon Pharmaceutical, Ferring Pharmaceuticals, Aju Pharm, Santen Pharmaceutical, Handok, Hutecs Korea, Myung in Pharm, MSD, Daiichi Sankyo, and Johnson & Johnson recorded double-digit growth.
Among them, MSD is the only pharmaceutical company that recorded more than KRW 100 billion in quarterly sales that achieved double-digit growth.
On the other hand, Youngil Pharm, which generated KRW 12.8 billion in sales last year, saw its sales plunge more than half top KRW 5.4 billion in the first quarter.
Sales of the three companies, Biogen, Sama Pharmaceutical, and Dong-A ST, decreased by more than 20%, while Kolon Pharmaceutical, Vivozon, Unimed, Hanwha Pharma, Korean Drug, Daewon Pharmaceutical, Ahn-Gook Pharmaceutical, Kuhnil Pharmaceutical, Sandoz, Samchundang Pharm, Pfizer, and GSK also recorded negative double-digit growth.
Meanwhile, out of 21 pharmaceutical companies with double-digit growth in the first quarter, 12 were Korean and nine were foreign.
Among the 16 companies that recorded negative double-digit growth, Korean companies accounted for most of them with 12, showing a slump.
